Adenosquamous Carcinoma of the Lung: Survival, Radiologic Findings, PD-L1, and Driver Mutations

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Oct 16

PMID 39407771

Authors

Oliver Illini

Hannah Fabikan

Eva Fischer

Anna Sophie Lang-Stoberl

Dagmar Krenbek

Christa Jarius

Shokoufa Azarnia-Medan

Stefan Gasser

Maximilian Johannes Hochmair

Christoph Weinlinger

Arschang Valipour

Stefan Watzka

Affiliations

Soon will be listed here.

Abstract

Adenosquamous carcinoma of the lung (ASC) is a rare non-small-cell lung cancer (NSCLC) subtype combining components of squamous cell carcinoma (SCC) and adenocarcinoma (AC). Data on ASC, particularly in Caucasian populations, are limited. We reviewed clinicopathological and radiological characteristics of ASC patients diagnosed between 1996 and 2023. Patients were classified into AC-predominant ASC (AC-ASC) and SCC-predominant ASC (SCC-ASC) groups for analysis. Among the 66 patients included, the median overall survival was 41.7 (95% CI, 25.0-54.4), while it was 48.1 (95% CI, 27.3-88.0) in patients treated with curative surgery (n = 44) and 15.3 (95% CI, 6.5-42.6) months for palliative patients (n = 22). The five-year survival rates were 39% and 26%, respectively. Recurrence occurred in 43% of stage I patients and was associated with worse survival (HR 3.303 (95% CI, 1.10-9.89) = 0.033). AC-ASCs (n = 17) more frequently showed air-bronchogram ( = 0.002) and pleural effusions ( = 0.054) compared to SCC-ASCs (n = 26). SCC-ASCs exhibited more vascular invasion ( = 0.006) and PD-L1 values between 1 and 49% (TPS) ( = 0.032). The subtype did not influence survival. EGFR and ALK alterations were found in 17% and 2% of patients, respectively. Despite early-stage disease, ASC patients had a high recurrence rate, associated with worse survival. Clinicopathologic differences between AC-ASCs and SCC-ASCs did not influence survival.

References

Li C, Zheng X, Li P, Wang H, Hu J, Wu L . Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma. Front Immunol. 2022; 13:944812. PMC: 9413057. DOI: 10.3389/fimmu.2022.944812. View

Planchard D, Janne P, Cheng Y, Yang J, Yanagitani N, Kim S . Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC. N Engl J Med. 2023; 389(21):1935-1948. DOI: 10.1056/NEJMoa2306434. View

Nakagawa K, Yasumitu T, Fukuhara K, Shiono H, Kikui M . Poor prognosis after lung resection for patients with adenosquamous carcinoma of the lung. Ann Thorac Surg. 2003; 75(6):1740-4. DOI: 10.1016/s0003-4975(03)00022-5. View

Vassella E, Langsch S, Dettmer M, Schlup C, Neuenschwander M, Frattini M . Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?. Oncotarget. 2015; 6(27):23905-16. PMC: 4695160. DOI: 10.18632/oncotarget.4163. View

Yip S, Liu Y, Parmar C, Li Q, Liu S, Qu F . Associations between radiologist-defined semantic and automatically computed radiomic features in non-small cell lung cancer. Sci Rep. 2017; 7(1):3519. PMC: 5471260. DOI: 10.1038/s41598-017-02425-5. View

Detterbeck F, Boffa D, Kim A, Tanoue L . The Eighth Edition Lung Cancer Stage Classification. Chest. 2016; 151(1):193-203. DOI: 10.1016/j.chest.2016.10.010. View

Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y . Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. N Engl J Med. 2019; 382(1):41-50. DOI: 10.1056/NEJMoa1913662. View

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C . Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361(10):958-67. DOI: 10.1056/NEJMoa0904554. View

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. DOI: 10.1001/jama.2013.281053. View

10.

Cheng C, Luo Z, Xiong W, Shi Z, Tan H . Epidemiology and survival outcomes in adenosquamous carcinoma: a population-based study. Int J Colorectal Dis. 2022; 37(7):1581-1592. DOI: 10.1007/s00384-022-04198-4. View

11.

Liu Y, Zhu Y, Bai L, Chen F, Wang J, Guo Y . Adenocarcinomatous-predominant subtype associated with a better prognosis in adenosquamous lung carcinoma. BMC Cancer. 2020; 20(1):520. PMC: 7275572. DOI: 10.1186/s12885-020-06972-5. View

12.

Shi X, Wu S, Sun J, Liu Y, Zeng X, Liang Z . PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer. Sci Rep. 2017; 7:46209. PMC: 5384250. DOI: 10.1038/srep46209. View

13.

Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beasley M . The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9):1243-1260. DOI: 10.1097/JTO.0000000000000630. View

14.

Hlaing A, Furusato B, Udo E, Kitamura Y, Souda M, Masutani M . Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung. Biochem Biophys Res Commun. 2018; 503(4):2764-2769. DOI: 10.1016/j.bbrc.2018.08.037. View

15.

Wu Y, Dziadziuszko R, Ahn J, Barlesi F, Nishio M, Lee D . Alectinib in Resected -Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024; 390(14):1265-1276. DOI: 10.1056/NEJMoa2310532. View

16.

Gawrychowski J, Brulinski K, Malinowski E, Papla B . Prognosis and survival after radical resection of primary adenosquamous lung carcinoma. Eur J Cardiothorac Surg. 2005; 27(4):686-92. DOI: 10.1016/j.ejcts.2004.12.030. View

17.

Tomita M, Matsuzaki Y, Shimizu T, Hara M, Ayabe T, Onitsuka T . Prognostic determinants for lung cancer patients with preoperative high serum carcinoembryonic antigen levels. Thorac Cardiovasc Surg. 2005; 53(5):300-4. DOI: 10.1055/s-2005-865671. View

18.

Shimizu J, Oda M, Hayashi Y, Nonomura A, Watanabe Y . A clinicopathologic study of resected cases of adenosquamous carcinoma of the lung. Chest. 1996; 109(4):989-94. DOI: 10.1378/chest.109.4.989. View

19.

Hu M, Zhang B, Xu J, Wang S, Zhao Y, Zhang L . Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma. Mol Diagn Ther. 2019; 23(6):773-779. DOI: 10.1007/s40291-019-00425-x. View

20.

Li C, Lu H . Adenosquamous carcinoma of the lung. Onco Targets Ther. 2018; 11:4829-4835. PMC: 6098426. DOI: 10.2147/OTT.S164574. View